(SLGN) Silgan Holdings - Overview
Stock: Dispensing Closures, Metal Cans, Custom Plastic Containers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.71% |
| Yield on Cost 5y | 2.26% |
| Yield CAGR 5y | 9.33% |
| Payout Consistency | 65.5% |
| Payout Ratio | 21.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.7% |
| Relative Tail Risk | -9.61% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -20.20 |
| Character TTM | |
|---|---|
| Beta | 0.633 |
| Beta Downside | 0.582 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.70% |
| CAGR/Max DD | -0.06 |
Description: SLGN Silgan Holdings January 08, 2026
Silgan Holdings Inc. (NYSE: SLGN) manufactures rigid packaging solutions for consumer-goods manufacturers in the U.S. and abroad, operating through three segments: Dispensing & Specialty Closures, Metal Containers, and Custom Containers.
The Dispensing & Specialty Closures segment supplies proprietary metal and plastic closures, capping equipment, and fragrance-detection systems to the food, beverage, personal-care, and home-care markets. The Metal Containers business produces steel and aluminum cans for pet food, soups, proteins, and other shelf-stable foods, while the Custom Containers segment offers high-density polyethylene (HDPE) and PET trays, thermoformed bowls, and specialty plastic fitments for both food and household products. Sales are driven primarily by a direct sales force, supplemented by distributors and an online catalog.
In FY 2023 Silgan reported revenue of roughly $2.5 billion with an adjusted EBITDA margin near 10%, reflecting modest pricing power but sensitivity to raw-material costs (steel, aluminum, resin). Key economic drivers include food-price inflation, which boosts demand for durable metal cans, and the continued shift toward e-commerce packaging that favors high-volume, low-cost closures. The company’s exposure to commodity price volatility and its ability to pass through cost increases remain central to earnings outlook.
For a deeper quantitative view of SLGN’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 312.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.06 > 1.0 |
| NWC/Revenue: 13.37% < 20% (prev 4.70%; Δ 8.67% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.29b > Net Income 312.8m |
| Net Debt (3.27b) to EBITDA (673.6m): 4.85 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.8m) vs 12m ago -1.40% < -2% |
| Gross Margin: 16.94% > 18% (prev 0.17%; Δ 1677 % > 0.5%) |
| Asset Turnover: 77.33% > 50% (prev 68.20%; Δ 9.13% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBITDA TTM 673.6m / Interest Expense TTM 190.6m) |
Altman Z'' 2.56
| A: 0.10 (Total Current Assets 2.75b - Total Current Liabilities 1.82b) / Total Assets 9.40b |
| B: 0.38 (Retained Earnings 3.61b / Total Assets 9.40b) |
| C: 0.05 (EBIT TTM 430.4m / Avg Total Assets 8.99b) |
| D: 0.32 (Book Value of Equity 2.27b / Total Liabilities 7.12b) |
| Altman-Z'' Score: 2.56 = A |
Beneish M -3.10
| DSRI: 0.84 (Receivables 589.4m/594.3m, Revenue 6.95b/5.85b) |
| GMI: 1.02 (GM 16.94% / 17.28%) |
| AQI: 1.03 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 1.19 (Revenue 6.95b / 5.85b) |
| TATA: -0.10 (NI 312.8m - CFO 1.29b) / TA 9.40b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of SLGN shares?
Over the past week, the price has changed by +12.71%, over one month by +13.92%, over three months by +28.35% and over the past year by -7.09%.
Is SLGN a buy, sell or hold?
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SLGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.2 | 11.3% |
| Analysts Target Price | 54.2 | 11.3% |
| ValueRay Target Price | 48.6 | -0.1% |
SLGN Fundamental Data Overview February 07, 2026
P/E Forward = 12.7877
P/S = 0.8065
P/B = 2.2306
P/EG = 0.8384
Revenue TTM = 6.95b USD
EBIT TTM = 430.4m USD
EBITDA TTM = 673.6m USD
Long Term Debt = 3.81b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.13b USD (from shortLongTermDebt, two quarters ago)
Debt = 4.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.27b USD (from netDebt column, last quarter)
Enterprise Value = 8.49b USD (5.23b + Debt 4.35b - CCE 1.08b)
Interest Coverage Ratio = 2.26 (Ebit TTM 430.4m / Interest Expense TTM 190.6m)
EV/FCF = 8.69x (Enterprise Value 8.49b / FCF TTM 977.7m)
FCF Yield = 11.51% (FCF TTM 977.7m / Enterprise Value 8.49b)
FCF Margin = 14.06% (FCF TTM 977.7m / Revenue TTM 6.95b)
Net Margin = 4.50% (Net Income TTM 312.8m / Revenue TTM 6.95b)
Gross Margin = 16.94% ((Revenue TTM 6.95b - Cost of Revenue TTM 5.78b) / Revenue TTM)
Gross Margin QoQ = 17.21% (prev 16.29%)
Tobins Q-Ratio = 0.90 (Enterprise Value 8.49b / Total Assets 9.40b)
Interest Expense / Debt = 1.10% (Interest Expense 47.7m / Debt 4.35b)
Taxrate = 29.95% (123.3m / 411.7m)
NOPAT = 301.5m (EBIT 430.4m * (1 - 29.95%))
Current Ratio = 1.51 (Total Current Assets 2.75b / Total Current Liabilities 1.82b)
Debt / Equity = 1.91 (Debt 4.35b / totalStockholderEquity, last quarter 2.27b)
Debt / EBITDA = 4.85 (Net Debt 3.27b / EBITDA 673.6m)
Debt / FCF = 3.34 (Net Debt 3.27b / FCF TTM 977.7m)
Total Stockholder Equity = 2.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 312.8m / Total Assets 9.40b)
RoE = 14.13% (Net Income TTM 312.8m / Total Stockholder Equity 2.21b)
RoCE = 7.14% (EBIT 430.4m / Capital Employed (Equity 2.21b + L.T.Debt 3.81b))
RoIC = 4.27% (NOPAT 301.5m / Invested Capital 7.07b)
WACC = 4.85% (E(5.23b)/V(9.58b) * Re(8.25%) + D(4.35b)/V(9.58b) * Rd(1.10%) * (1-Tc(0.30)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.52%
[DCF Debug] Terminal Value 87.00% ; FCFF base≈770.3m ; Y1≈825.8m ; Y5≈1.00b
Fair Price DCF = 250.6 (EV 29.74b - Net Debt 3.27b = Equity 26.48b / Shares 105.7m; r=5.90% [WACC]; 5y FCF grow 8.09% → 2.90% )
EPS Correlation: -5.24 | EPS CAGR: -3.97% | SUE: 1.15 | # QB: 1
Revenue Correlation: 19.43 | Revenue CAGR: 0.49% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.75 | Chg30d=-0.029 | Revisions Net=-1 | Analysts=9
EPS current Year (2026-12-31): EPS=3.81 | Chg30d=-0.022 | Revisions Net=-3 | Growth EPS=+2.4% | Growth Revenue=+2.7%
EPS next Year (2027-12-31): EPS=4.11 | Chg30d=-0.067 | Revisions Net=-4 | Growth EPS=+7.8% | Growth Revenue=+2.1%